Company Information

BAL PHARMA LTD.

NSE : BALPHARMABSE : 524824ISIN CODE : INE083D01012Industry : Pharmaceuticals & DrugsHouse : Private
BSE100.88-0.2 (-0.2 %)
PREV CLOSE ( ) 101.08
OPEN PRICE ( ) 102.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 935
TODAY'S LOW / HIGH ( )100.88 102.20
52 WK LOW / HIGH ( )71 132.2
NSE100.60-0.65 (-0.64 %)
PREV CLOSE( ) 101.25
OPEN PRICE ( ) 101.00
BID PRICE (QTY) 100.60 (52)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6289
TODAY'S LOW / HIGH( ) 100.00 103.95
52 WK LOW / HIGH ( )77.5 132.45
Managing DirectorShailesh Siroya
Company SecretaryAbdul Basith
Executive DirectorHimesh Virupakshaya
Kotian Chittananda Damodar
Non Executive Independent DirectorCV Srinivas
Nicloa Neeladri
Jatish Sheth
HS Venkatesh
Incorporation Year : 1987

Registered Office :

Address : #21&22, Bommasandra Industrial Area,Anekal Taluk, Bengaluru,
Karnataka-560099 .

Phone : 080 41570811 / 13 / 19

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.